The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack
Open accessAbstract
IMPORTANCE: Data are limited regarding the association between CYP2C19 genetic variants and clinical outcomes of patients with minor stroke or transient ischemic attack treated with clopidogrel. OBJECTIVE: To estimate the association between CYP2C19 genetic variants and clinical outcomes of clopidogrel-treated patients with minor stroke or transient ischemic attack. DESIGN, SETTING, AND PARTICIPANTS: Three CYP2C19 major alleles (*2, *3, *17) were genotyped among 2933 Chinese patients from 73 sites who were enrolled in the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) randomized trial conducted from January 2, 2010, to March 20, 2012. INTERVENTIONS: Patients with acute minor ischemic stroke or transient ischemic attack in the trial were randomized to treatment with clopidogrel combined with aspirin or to aspirin alone. MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was new stroke. The secondary efficacy outcome was a composite of new composite vascular events (ischemic stroke, hemorrhagic stroke, myocardial infarction, or vascular death). Bleeding was the safety outcome. RESULTS: Among 2933 patients, 1948 (66.4%) were men, with a mean age of 62.4 years. Overall, 1207 patients (41.2%) were noncarriers and 1726 patients (58.8%) were carriers of loss-of-function alleles (*2, *3). After day 90 follow-up, clopidogrel-aspirin reduced the rate of new stroke in the noncarriers but not in the carriers of the loss-of-function alleles (P = .02 for interaction; events among noncarriers, 41 [6.7%] with clopidogrel-aspirin vs 74 [12.4%] with aspirin; hazard ratio [HR], 0.51 [95% CI, 0.35-0.75]; events among carriers, 80 [9.4%] with clopidogrel-aspirin vs 94 [10.8%] with aspirin; HR, 0.93 [95% CI, 0.69 to 1.26]). Similar results were observed for the secondary composite efficacy outcome (noncarriers: 41 [6.7%] with clopidogrel-aspirin vs 75 [12.5%] with aspirin; HR, 0.50 [95% CI, 0.34-0.74]; carriers: 80 [9.4%] with clopidogrel-aspirin vs 95 [10.9%] with aspirin; HR, 0.92 [95% CI, 0.68-1.24]; P = .02 for interaction). The effect of treatment assignment on bleeding did not vary significantly between the carriers and the noncarriers of the loss-of-function alleles (2.3% for carriers and 2.5% for noncarriers in the clopidogrel-aspirin group vs 1.4% for carriers and 1.7% for noncarriers in the aspirin only group; P = .78 for interaction). CONCLUSIONS AND RELEVANCE: Among patients with minor ischemic stroke or transient ischemic attack, the use of clopidogrel plus aspirin compared with aspirin alone reduced the risk of a new stroke only in the subgroup of patients who were not carriers of the CYP2C19 loss-of-function alleles. These findings support a role of CYP2C19 genotype in the efficacy of this treatment. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00979589.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adams, H. P., Bendixen, B. H., Kappelle, L. J., Biller, J., Love, B. B., Gordon, D. L., & Marsh, E. E. (1993) · Stroke · doi:10.1161/01.str.24.1.35 · Cited by 12,335
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Self-citation(1993) · New England Journal of Medicine · doi:10.1056/nejm199309023291001 · Cited by 4,055
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809171 · Cited by 2,497
Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic Attack
Wang, Y., Wang, Y., Zhao, X., Liu, L., Wang, D., Wang, C., Wang, C., Li, H., Meng, X., Cui, L., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215340 · Cited by 1,854
Self-citationGenetic Determinants of Response to Clopidogrel and Cardiovascular Events
Simon, T., Verstuyft, C., Mary-Krause, M., Quteineh, L., Drouet, E., Méneveau, N., Steg, P. G., Ferrières, J., Danchin, N., & Becquemont, L. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808227 · Cited by 1,728
Scott, S. A., Sangkuhl, K., Stein, C. M., Hulot, J.-S., Mega, J. L., Roden, D. M., Klein, T. E., Sabatine, M. S., Johnson, J. A., & Shuldiner, A. R. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.105 · Cited by 962
Hulot, J.-S. (2006) · Blood · doi:10.1182/blood-2006-04-013052 · Cited by 931
SIM, S., RISINGER, C., DAHL, M., AKLILLU, E., CHRISTENSEN, M., BERTILSSON, L., & INGELMANSUNDBERG, M. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.10.002 · Cited by 732
Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment
Paré, G., Mehta, S. R., Yusuf, S., Anand, S. S., Connolly, S. J., Hirsh, J., Simonsen, K., Bhatt, D. L., Fox, K. A. A., & Eikelboom, J. W. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008410 · Cited by 534
Scott, S. A., Sangkuhl, K., Gardner, E. E., Stein, C. M., Hulot, J.-S., Johnson, J. A., Roden, D. M., Klein, T. E., & Shuldiner, A. R. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.132 · Cited by 484
Holmes, M. V., Perel, P., Shah, T., Hingorani, A. D., & Casas, J. P. (2011) · JAMA · doi:10.1001/jama.2011.1880 · Cited by 472
Roberts, J. D., Wells, G. A., Le May, M. R., Labinaz, M., Glover, C., Froeschl, M., Dick, A., Marquis, J.-F., O'Brien, E., Goncalves, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60161-5 · Cited by 391
Zhao, D., Liu, J., Wang, W., Zeng, Z., Cheng, J., Liu, J., Sun, J., & Wu, Z. (2008) · Stroke · doi:10.1161/strokeaha.107.502807 · Cited by 347
Bauer, T., Bouman, H. J., van Werkum, J. W., Ford, N. F., ten Berg, J. M., & Taubert, D. (2011) · BMJ · doi:10.1136/bmj.d4588 · Cited by 266
Pharmacogenomic testing: Relevance in medical practice
Kitzmiller, J. P., Groen, D. K., Phelps, M. A., & Sadée, W. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.78a.10145 · Cited by 151
Wang, Y., Liu, M., & Pu, C. (2017) · International Journal of Stroke · doi:10.1177/1747493017694391 · Cited by 143
Self-citationWang, Y., Zhang, S., Zhang, L., & Wang, C. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2011.00290.x · Cited by 115
Self-citationHasan, M. S., Basri, H., Hin, L. P., & Stanslas, J. (2012) · International Journal of Neuroscience · doi:10.3109/00207454.2012.744308 · Cited by 113
CYP2C19 Polymorphisms and Antiplatelet Effects of Clopidogrel in Acute Ischemic Stroke in China
Jia, D., Chen, Z. Z., Zhang, M., et al. (2013) · Stroke · doi:10.1161/strokeaha.113.000823 · Cited by 106
Cytochrome P-450 polymorphisms and response to clopidogrel
Marian, A. J. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0025-7 · Cited by 77
Wang, Y. L., Wu, D., Liao, X., Zhang, W., Zhao, X., & Wang, Y. J. (2007) · International Journal of Stroke · doi:10.1111/j.1747-4949.2007.00142.x · Cited by 71
Self-citationReview: Platelet Function Testing and Implications for Clinical Practice
Collet, J., & Montalescot, G. (2009) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248409339309 · Cited by 59
McDonough, C. W., McClure, L. A., Mitchell, B. D., Gong, Y., Horenstein, R. B., Lewis, J. P., Field, T. S., Talbert, R. L., Benavente, O., Johnson, J. A., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001652 · Cited by 58
Prevalence, knowledge, and treatment of transient ischemic attacks in China
Wang, Y., Zhao, X., Jiang, Y., Li, H., Wang, L., Johnston, S. C., Liu, L., Wong, K. S., Wang, C., Pan, Y., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001665 · Cited by 55
Self-citationSun, W., Li, Y., Li, J., Zhang, Z., Zhu, W., Liu, W., Cai, Q., Wang, X., Cao, L., Bai, W., et al. (2014) · Platelets · doi:10.3109/09537104.2014.953044 · Cited by 48
Genetics of platelet inhibitor treatment
Trenk, D., & Hochholzer, W. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12230 · Cited by 47
Osnabrugge, R. L. J., Head, S. J., Zijlstra, F., ten Berg, J. M., Hunink, M. G. M., Kappetein, A. P., & Janssens, A. C. J. W. (2014) · Genetics in Medicine · doi:10.1038/gim.2014.76 · Cited by 46
Li, Z., Wang, Y., Zhao, X., Liu, L., Wang, D., Wang, C., Meng, X., Li, H., Pan, Y., Wang, X., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.003038 · Cited by 30
Self-citationStockman, J. A. (2012) · Yearbook of Pediatrics · doi:10.1016/j.yped.2012.03.021 · Cited by 28
Holmes, M. V., Perel, P., Shah, T., Hingorani, A. D., & Casas, J. (2011) · UCL Discovery (University College London) · Cited by 27
Buckley, P. F. (2007) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(08)70611-x · Cited by 15
CYP2C19 polymorphism and antiplatelet effects of clopidogrel in Chinese stroke patients.
Yang, J., Zhao, H.-D., Tan, J. E., Ding, Y., Gu, Z., & Zou, J. (2013) · PubMed · Cited by 13
Cited by
Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., et al. (2019) · Stroke · doi:10.1161/str.0000000000000211 · Cited by 7,468
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA
Johnston, S. C., Easton, J. D., Farrant, M., Barsan, W., Conwit, R. A., Elm, J. J., Kim, A. S., Lindblad, A. S., & Palesch, Y. Y. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1800410 · Cited by 1,352
Self-citationHankey, G. J. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30962-x · Cited by 1,226
Hilkens, N. A., Casolla, B., Leung, T. W., & de Leeuw, F.-E. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00642-1 · Cited by 681
Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA
Wang, Y., Meng, X., Wang, A., Xie, X., Pan, Y., Johnston, S. C., Li, H., Bath, P. M., Dong, Q., Xu, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2111749 · Cited by 395
Self-citation
Metadata
- Authors
- Wang, Y., Zhao, X., Lin, J., Li, H., Johnston, S. C., Lin, Y., Pan, Y., Liu, L., Wang, D., Wang, C., Meng, X., Xu, J., Wang, Y., & for the CHANCE investigators
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-07-05
- Volume
- 316
- Issue
- 1
- Pages
- 70
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2460117772
- Cited by
- 375
- References
- 33
- FWCI
- 25.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.